Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

TASC, 2000, Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC), Eur J Vasc Endovasc Surg, 19, Si

TASC, 2000, Management of Peripheral Arterial Disease (PAD) TransAtlantic Intersociety Consensus (TASC), J Vasc Surg, 31, S1

TASC, 2000, Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC), Int Angiol, 19, I

Clement, 2000, A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis), Int Angiol, 19, 97

Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extermity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interverntions, Society for Vascular Medicine and Biology, Society of Interventional Raidology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47:1239-312.

AHCPR. United States Department of Health and Human Services, 1993

Criqui, 1985, The prevalence of peripheral arterial disease in a defined population, Circulation, 71, 510, 10.1161/01.CIR.71.3.510

Hiatt, 1995, Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study, Circulation, 91, 1472, 10.1161/01.CIR.91.5.1472

Selvin, 2004, Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000, Circulation, 110, 738, 10.1161/01.CIR.0000137913.26087.F0

Fowkes, 1991, Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population, Int J Epidemiol, 20, 384, 10.1093/ije/20.2.384

Hirsch, 2001, Peripheral arterial disease detection, awareness, and treatment in primary care, JAMA, 286, 1317, 10.1001/jama.286.11.1317

Criqui, 2005, Ethnicity and peripheral arterial disease: the San Diego Population Study, Circulation, 112, 2703, 10.1161/CIRCULATIONAHA.105.546507

Kullo, 2003, Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study, Vasc Med, 8, 237, 10.1191/1358863x03vm511oa

Selvin, 2004, Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus, Ann Intern Med, 141, 421, 10.7326/0003-4819-141-6-200409210-00007

Muntner, 2005, Relationship between HbA1c level and peripheral arterial disease, Diabetes Care, 28, 1981, 10.2337/diacare.28.8.1981

ADA, 2003, Peripheral arterial disease in people with diabetes, Diabetes Care, 26, 3333

Senti, 1992, Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes, Circulation, 85, 30, 10.1161/01.CIR.85.1.30

Ridker, 2001, Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease, JAMA, 285, 2481, 10.1001/jama.285.19.2481

O'Hare, 2004, Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS), J Am Soc Nephrol, 15, 1046, 10.1097/01.ASN.0000119574.27772.FD

McDermott, 2004, Leg strength in peripheral arterial disease: associations with disease severity and lower-extremity performance, J Vasc Surg, 39, 523, 10.1016/j.jvs.2003.08.038

Widmer, 1985, Risk profile and occlusive peripheral arterial disease, Proceedings of 13th International Congress of Angiology, 28

Kannel, 1970, Intermittent claudication. Incidence in the Framingham Study, Circulation, 41, 875, 10.1161/01.CIR.41.5.875

Rothwell, 2004, Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery, Lancet, 363, 915, 10.1016/S0140-6736(04)15785-1

Tunis, 1991, The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease, N Engl J Med, 325, 556, 10.1056/NEJM199108223250806

Dormandy, 1994, Prospective study of 713 below-knee amputations for ischaemia and the effect of a prostacyclin analogue on healing. Hawaii Study Group, Br J Surg, 81, 33, 10.1002/bjs.1800810110

Bhatt, 2006, International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis, JAMA, 295, 180, 10.1001/jama.295.2.180

Aronow, 1994, Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age, Am J Cardiol, 74, 64, 10.1016/0002-9149(94)90493-6

Dormandy, 1991, The fate of the claudicant–a prospective study of 1969 claudicants, Eur J Vasc Surg, 5, 131, 10.1016/S0950-821X(05)80676-0

Mehler, 2003, Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes, Circulation, 107, 753, 10.1161/01.CIR.0000049640.46039.52

Criqui, 1992, Mortality over a period of 10 years in patients with peripheral arterial disease, N Engl J Med, 326, 381, 10.1056/NEJM199202063260605

Fowkes, 2005, On behalf of the ABI collaboration. Ankle-brachial index as an independent indicator of mortality in fifteen international population cohort studies, Circulation, 112, 3704

CAPRIE, 1996, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee, Lancet, 348, 1329

HPSCG, 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7

Resnick, 2004, Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study, Circulation, 109, 733, 10.1161/01.CIR.0000112642.63927.54

Critchley, 2003, Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review, JAMA, 290, 86, 10.1001/jama.290.1.86

Anthonisen, 2005, The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial, Ann Intern Med, 142, 233, 10.7326/0003-4819-142-4-200502150-00005

Tonstad, 2003, Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study, Eur Heart J, 24, 946, 10.1016/S0195-668X(03)00003-4

Jorenby, 1999, A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation, N Engl J Med, 340, 685, 10.1056/NEJM199903043400903

Willigendael, 2005, Smoking and the patency of lower extremity bypass grafts: a meta-analysis, J Vasc Surg, 42, 67, 10.1016/j.jvs.2005.03.024

Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267

De Backer, 2004, Atherosclerosis, 173, 381

Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E

Smith, 2001, Circulation, 104, 1577, 10.1161/hc3801.097475

Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604

Blankenhorn, 1991, Effects of colestipol-niacin therapy on human femoral atherosclerosis, Circulation, 83, 438, 10.1161/01.CIR.83.2.438

Taylor, 2004, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins, Circulation, 110, 3512, 10.1161/01.CIR.0000148955.19792.8D

Chobanian, 2003, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2

ESH/ESC, 2003, 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension, J Hypertens, 21, 1011

Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med, 342, 145

Radack, 1991, Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials, Arch Intern Med, 151, 1769, 10.1001/archinte.1991.00400090063012

UKPDS, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837

DCCT, 1995, Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial, Am J Cardiol, 75, 894

ADA, 2006, Standards of medical care in diabetes–2006, Diabetes Care, 29, S4

Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9

Bonaa, 2006, Homocysteine lowering and cardiovascular events after acute myocardial infarction, N Engl J Med, 354, 1578, 10.1056/NEJMoa055227

Lonn, 2006, Homocysteine lowering with folic acid and B vitamins in vascular disease, N Engl J Med, 354, 1567

ATC, 2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, Br Med J, 324, 71

ATC, 1994, Collaborative overview of randomised trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration, Br Med J, 308, 81

Clagett, 2004, Antithrombotic therapy in peripheral arterial disease: The Seventh ACCP Conference on antithrombotic and thrombolytic therapy, Chest, 126, S609, 10.1378/chest.126.3_suppl.609S

Neri Serneri, 2004, Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study, Eur Heart J, 25, 1845, 10.1016/j.ehj.2004.07.013

Janzon, 1990, Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study, J Intern Med, 227, 301, 10.1111/j.1365-2796.1990.tb00164.x

Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, 494

Bhatt, 2006, Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events, N Engl J Med, 354, 1706, 10.1056/NEJMoa060989

Murray, 2003, Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk, Lancet, 361, 717, 10.1016/S0140-6736(03)12655-4

Fischer, 2004, Economic implications of evidence-based prescribing for hypertension: can better care cost less?, JAMA, 291, 1850, 10.1001/jama.291.15.1850

Gaspoz, 2002, Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease, N Engl J Med, 346, 1800, 10.1056/NEJM200206063462309

Lancaster, 2000, Training health professionals in smoking cessation, Cochrane Database Syst Rev, CD000214

Song, 2002, Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis, Med Decis Making, 22, S26, 10.1177/027298902237708

Hillsdon, 2005, Interventions for promoting physical activity, Cochrane Database Syst Rev, CD003180

Lowensteyn, 2000, The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease, J Cardiopulm Rehabil, 20, 147, 10.1097/00008483-200005000-00002

Jones, 2004, Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation, Health Technol Assess, 8, iii

Mihaylova, 2005, Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals, Lancet, 365, 1779

Lamy, 2003, Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study, Circulation, 107, 960, 10.1161/01.CIR.0000050600.49419.25

Antman, 2004, Circulation, 110, e82

Gibbons, 2003, J Am Coll Cardiol, 41, 159, 10.1016/S0735-1097(02)02848-6

Eagle, 2002, J Am Coll Cardiol, 39, 542, 10.1016/S0735-1097(01)01788-0

McFalls, 2004, Coronary-artery revascularization before elective major vascular surgery, N Engl J Med, 351, 2795, 10.1056/NEJMoa041905

Poldermans, 2001, Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery, Eur Heart J, 22, 1353, 10.1053/euhj.2000.2555

Poldermans, 1999, The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group, N Engl J Med, 341, 1789, 10.1056/NEJM199912093412402

Kertai, 2003, Optimizing long-term cardiac management after major vascular surgery: Role of beta-blocker therapy, clinical characteristics, and dobutamine stress echocardiography to optimize long-term cardiac management after major vascular surgery, Arch Intern Med, 163, 2230, 10.1001/archinte.163.18.2230

Adams, 2003, Circulation, 108, 1278, 10.1161/01.CIR.0000090444.87006.CF

Chaturvedi, 2005, Carotid endarterectomy–an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Neurology, 65, 794, 10.1212/01.wnl.0000176036.07558.82

Rundback, 2003, Guidelines for the reporting of renal artery revascularization in clinical trials, J Vasc Interv Radiol, 14, S477, 10.1097/01.RVI.0000094621.61428.d5

Plouin, 2003, A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia, Int Angiol, 22, 333

McDermott, 2001, Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment, JAMA, 286, 1599, 10.1001/jama.286.13.1599

Criqui, 1985, The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population, Circulation, 71, 516, 10.1161/01.CIR.71.3.516

Gibbons, 2002, ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines), J Am Coll Cardiol, 40, 1531, 10.1016/S0735-1097(02)02164-2

Labs, 1999, Trans-atlantic conference on clinical trial guidelines in PAOD (Peripheral arterial occlusive disease) clinical trial methodology, Eur J Vasc Endovasc Surg, 18, 253, 10.1053/ejvs.1999.0931

Gardner, 1995, Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis, JAMA, 274, 975, 10.1001/jama.1995.03530120067043

Stewart, 2002, Exercise training for claudication, N Engl J Med, 347, 1941, 10.1056/NEJMra021135

Hiatt, 1994, Superiority of treadmill walking exercise vs. strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response, Circulation, 90, 1866, 10.1161/01.CIR.90.4.1866

Regensteiner, 2002, Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials, J Am Geriatr Soc, 50, 1939, 10.1046/j.1532-5415.2002.50604.x

Dawson, 2000, A comparison of cilostazol and pentoxifylline for treating intermittent claudication, Am J Med, 109, 523, 10.1016/S0002-9343(00)00569-6

Pratt, 2001, Analysis of the cilostazol safety database, Am J Cardiol, 87, 28D, 10.1016/S0002-9149(01)01719-2

Lehert, 1994, Naftidrofuryl in intermittent claudication: a retrospective analysis, J Cardiovasc Pharmacol, 23, S48, 10.1097/00005344-199400233-00010

Boccalon, 2001, Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication, Ann Cardiol Angeiol (Paris), 50, 175, 10.1016/S0003-3928(01)00016-6

Kieffer, 2001, A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS), Int Angiol, 20, 58

Spengel, 2002, Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program, Int Angiol, 21, 20

Brevetti, 1999, European multicenter study on Propionyl-l-carnitine in intermittent claudication, J Am Coll Cardiol, 34, 1618, 10.1016/S0735-1097(99)00373-3

Hiatt, 2001, Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication, Am J Med, 110, 616, 10.1016/S0002-9343(01)00704-5

Mohler, 2003, Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease, Circulation, 108, 1481, 10.1161/01.CIR.0000090686.57897.F5

Mondillo, 2003, Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease, Am J Med, 114, 359, 10.1016/S0002-9343(03)00010-X

Girolami, 1999, Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis, Arch Intern Med, 159, 337, 10.1001/archinte.159.4.337

Hood, 1996, Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials, CMAJ, 155, 1053

Moher, 2000, Pharmacological management of intermittent claudication: a meta- analysis of randomised trials, Drugs, 59, 1057, 10.2165/00003495-200059050-00003

Cosmi, 2001, Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication, Cochrane Database Syst Rev, CD001999

Coffman, 1979, Vasodilator drugs in peripheral vascular disease, N Engl J Med, 300, 713, 10.1056/NEJM197903293001305

Maxwell, 2000, Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar, Vasc Med, 5, 11

Hiatt, 2004, The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease, Vasc Med, 9, 271, 10.1191/1358863x04vm569oa

Thulesius, 1987, Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications, J Cardiovasc Pharmacol, 9, 728, 10.1097/00005344-198706000-00014

Verstraete, 1996, The PACK trial: morbidity and mortality effects of ketanserin. Prevention of atherosclerotic complications, Vasc Med, 1, 135, 10.1177/1358863X9600100209

Hiatt, 2004, Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy, Vasc Med, 9, 18, 10.1191/1358863x04vm520oa

Norgren, 2006, the European MCI-9042 Study Group. Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A phase II European Study, Vasc Med, 11, 75, 10.1191/1358863x06vm657oa

Belch, 1997, Randomised, placebo-controlled, double-blind study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication, Circulation, 95, 2298, 10.1161/01.CIR.95.9.2298

Lievre, 2000, Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group, Circulation, 102, 426, 10.1161/01.CIR.102.4.426

Mohler, 2003, Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial, J Am Coll Cardiol, 41, 1679, 10.1016/S0735-1097(03)00299-7

de Backer, 2001, Buflomedil for intermittent claudication, Cochrane Database Syst Rev, CD000988

de Backer, 2000, Oral vasoactive medication in intermittent claudication: utile or futile?, Eur J Clin Pharmacol, 56, 199, 10.1007/s002280000114

Laurora, 1994, Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study, Panminerva Med, 36, 83

Strano, 1991, A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease, Semin Thromb Hemost, 17, 228

Violi, 2000, Improvement of walking distance by defibrotide in patients with intermittent claudication–results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study, Thromb Haemost, 83, 672

Lederman, 2002, Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial, Lancet, 359, 2053, 10.1016/S0140-6736(02)08937-7

Rajagopalan, 2003, Circulation, 108, 1933, 10.1161/01.CIR.0000093398.16124.29

Armstrong, 1998, Diabetic foot ulcers: prevention, diagnosis and classification, Am Fam Physician, 57, 1325

Reiber, 1999, Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings, Diabetes Care, 22, 157, 10.2337/diacare.22.1.157

Armstrong, 2003, Activity patterns of patients with diabetic foot ulceration: patients with active ulceration may not adhere to a standard pressure off-loading regimen, Diabetes Care, 26, 2595, 10.2337/diacare.26.9.2595

Moulik, 2003, Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology, Diabetes Care, 26, 491, 10.2337/diacare.26.2.491

Strandness DJ, Sumner D. Hemodynamics for surgeons. New York: Grune & Stratton; 1975. p. 278-81.

Franzeck, 1982, Transcutaneous PO2 measurements in health and peripheral arterial occlusive disease, Surgery, 91, 156

Smith, 1996, The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia, Eur J Vasc Endovasc Surg, 11, 402, 10.1016/S1078-5884(96)80170-5

ADA, 1999, Consensus Development Conference on Diabetic Foot Wound Care (American Diabetes Association), Diabetes Care, 22, 1354

Nabuurs-Franssen, 2005, Total contact casting of the diabetic foot in daily practice: a prospective follow-up study, Diabetes Care, 28, 243, 10.2337/diacare.28.2.243

Lipsky, 2004, International consensus group on diagnosing and treating the infected diabetic foot. A report from the international consensus on diagnosing and treating the infected diabetic foot, Diabetes Metab Res Rev, 20, S68, 10.1002/dmrr.453

Frykberg, 2003, An evidence based approach to diabetic foot infections, Am J Surg, 186, S44, 10.1016/j.amjsurg.2003.10.008

Nehler, 2003, Is revascularization and limb salvage always the best treatment for critical limb ischemia?, J Vasc Surg, 37, 704, 10.1067/mva.2003.142

Cutson, 1996, Rehabilitation of the older lower limb amputee: a brief review, J Am Geriatr Soc, 44, 1388, 10.1111/j.1532-5415.1996.tb01415.x

Lim, 1967, Below-knee amputation for ischemic gangrene, Surg Gynecol Obstet, 125, 493

Poredos, 2005, Determination of amputation level in ischaemic limbs using tcPO2 measurement, Vasa, 34, 108, 10.1024/0301-1526.34.2.108

Ruckley, 1991, Skewflap versus long posterior flap in below-knee amputations: multicenter trial, J Vasc Surg, 13, 423, 10.1067/mva.1991.25644

Siriwardena, 1991, Factors influencing rehabilitation of arteriosclerotic lower limb amputees, J Rehabil Res Dev, 28, 35, 10.1682/JRRD.1991.07.0035

Hagberg, 1992, Function after through-knee compared with below-knee and above-knee amputation, Prosthet Orthot Int, 16, 168, 10.3109/03093649209164336

Houghton, 1992, Success rates for rehabilitation of vascular amputees: implications for preoperative assessment and amputation level, Br J Surg, 79, 753, 10.1002/bjs.1800790811

Stirnemann, 1992, Influence of failed arterial reconstruction on the outcome of major limb amputation, Surgery, 111, 363

McWhinnie, 1994, Rehabilitation outcome 5 years after 100 lower-limb amputations, Br J Surg, 81, 1596, 10.1002/bjs.1800811110

Nehler, 2003, Functional outcome in a contemporary series of major lower extremity amputations, J Vasc Surg, 38, 7, 10.1016/S0741-5214(03)00092-2

Balzer, 1987, Placebo-kontrollierte, doppel-blinde Multicenterstudie zur Wirksamkeit von Iloprost bei der Behandlung ischämischer Ruheschmerzen von Patienten mit peripheren arterillen Durchblutungsstörungen, Vasa, 20, 379

Brock, 1990, Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative, Schweiz Med Wochenschr, 120, 1477

Diehm, 1989, Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study, Dtsch Med Wochenschr, 114, 783, 10.1055/s-2008-1066673

Diehm, 1988, Intravenose prostaglandin E1-therapie bei patienten mit peripherer arterieller verschlusskrankheit (AVK) im Stadium III: Eine doppelblinde, placebo-kontrollierte studie, 133

Ciprostene Study Group, 1991, The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers, J Clin Pharmacol, 31, 81, 10.1002/j.1552-4604.1991.tb01891.x

UK Severe Limb Ischemia Study Group, 1991, Treatment of limb threatening ischemia with intravenous Iloprost: A randomised double-blind placebo controlled study, Eur J Vasc Surg, 5, 511, 10.1016/S0950-821X(05)80337-8

Guilmot, 1991, Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analoque of prostacyclin: results of a French Multicentre trial, Drug Invest, 3, 351, 10.1007/BF03259752

Norgren, 1990, A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb. A Scandinavian-Polish placebo controlled, randomised multicenter study, Eur J Vasc Surg, 4, 463, 10.1016/S0950-821X(05)80784-4

Sakaguchi, 1984, Prostaglandin E1 intra-arterial infusion therapy in patients with ischemic ulcer of the extremities, Int Angiol, 3, 39

Brass, 2006, Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia, J Vasc Surg, 43, 752, 10.1016/j.jvs.2005.11.041

Dorffler-Melly, 2003, Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery, Cochrane Database Syst Rev, CD000535

Smith, 2000, Intravenous naftidrofuryl for critical limb ischaemia, Cochrane Database Syst Rev, CD002070

European Study Group, 1995, Intravenous pentoxifyllin, Eur J Vasc Endovasc Surg, 9, 426

Norwegian Pentoxifyllin Multicenter Trial Group, 1996, Efficacy and clinical tolerance of parenteral pentoxifyllin, Int Angiol, 15, 75

Kranke, 2004, Cochrane Database Syst Rev, CD004123

Ubbink, 2003, Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia, Cochrane Database Syst Rev, CD004001

Cardenas, 2001, A bibliography of cost-effectiveness practices in physical medicine and rehabilitation: AAPM&R white paper, Arch Phys Med Rehabil, 82, 711, 10.1053/apmr.2001.24814

Oostenbrink, 2001, Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery, J Vasc Surg, 34, 254, 10.1067/mva.2001.115961

Sarac, 2004, Clinical and economic evaluation of the trellis thrombectomy device for arterial occlusions: preliminary analysis, J Vasc Surg, 39, 556, 10.1016/j.jvs.2003.10.061

Whatling, 2000, Iliac occlusions: stenting or crossover grafting? An examination of patency and cost, Eur J Vasc Endovasc Surg, 20, 36, 10.1053/ejvs.2000.1113

Wixon, 2000, An economic appraisal of lower extremity bypass graft maintenance, J Vasc Surg, 32, 1, 10.1067/mva.2000.107307

Baumgartner, 1998, Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia, Circulation, 97, 1114, 10.1161/01.CIR.97.12.1114

Yla-Herttuala, 2003, Gene transfer as a tool to induce therapeutic vascular growth, Nat Med, 9, 694, 10.1038/nm0603-694

Tateishi-Yuyama, 2002, Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial, Lancet, 360, 427, 10.1016/S0140-6736(02)09670-8

Norgren, 2000, Pharmacotherapy for critical limb ischaemia, Diabetes Metab Res Rev, 16, S37, 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR108>3.0.CO;2-E

Collinson, 2004, Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation?, Eur J Vasc Endovasc Surg, 28, 9, 10.1016/j.ejvs.2004.03.021

Berridge, 2002, Surgery versus thrombolysis for initial management of acute limb ischaemia, Cochrane Database Syst Rev, 10.1002/14651858.CD002784

Campbell, 1998, Current management of acute leg ischaemia: results of an audit by the Vascular Surgical Society of Great Britain and Ireland, Br J Surg, 85, 1498, 10.1046/j.1365-2168.1998.00906.x

1994, Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial, Ann Surg, 220, 251, 10.1097/00000658-199409000-00003

Rutherford, 1997, Recommended standards for reports dealing with lower extremity ischemia: revised version, J Vasc Surg, 26, 517, 10.1016/S0741-5214(97)70045-4

Kuukasjarvi, 1994, Perioperative outcome of acute lower limb ischaemia on the basis of the national vascular registry. The Finnvasc Study Group, Eur J Vasc Surg, 8, 578, 10.1016/S0950-821X(05)80594-8

Eliason, 2003, A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia, Ann Surg, 238, 382, 10.1097/01.sla.0000086663.49670.d1

Ouriel, 1994, A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia, J Vasc Surg, 19, 1021, 10.1016/S0741-5214(94)70214-4

Ouriel, 1998, A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators, N Engl J Med, 338, 1105, 10.1056/NEJM199804163381603

Korn, 2001, Thrombolysis for native arterial occlusions of the lower extremities: clinical outcome and cost, J Vasc Surg, 33, 1148, 10.1067/mva.2001.114818

Saket, 2004, Novel intravascular ultrasound-guided method to create transintimal arterial communications: initial experience in peripheral occlusive disease and aortic dissection, J Endovasc Ther, 11, 274, 10.1583/03-1133.1

Becker, 1989, Noncoronary angioplasty, Radiology, 170, 921, 10.1148/radiology.170.3.2521745

Rutherford, 1992, Percutaneous ballon angioplasty for arteriosclerosis obliterans: long term results, 329

Murphy, 2004, Aortoiliac insufficiency: long-term experience with stent placement for treatment, Radiology, 231, 243, 10.1148/radiol.2311030408

Timaran, 2001, External iliac and common iliac artery angioplasty and stenting in men and women, J Vasc Surg, 34, 440, 10.1067/mva.2001.117148

Tetteroo, 1998, Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group, Lancet, 351, 1153, 10.1016/S0140-6736(97)09508-1

Klein, 2004, Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with iliac artery disease: The Dutch Iliac Stent Trial Study, Radiology, 232, 491, 10.1148/radiol.2322030725

Bosch, 1997, Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease, Radiology, 204, 87, 10.1148/radiology.204.1.9205227

Ponec, 2004, The Nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty: CRISP-US Trial results, J Vasc Interv Radiol, 15, 911, 10.1097/01.RVI.0000140935.45313.35

Reed, 2003, The impact of patient age and aortic size on the results of aortobifemoral bypass grafting, J Vasc Surg, 37, 1219, 10.1016/S0741-5214(02)75179-3

de Vries, 1997, Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis, J Vasc Surg, 26, 558, 10.1016/S0741-5214(97)70053-3

Muradin, 2001, Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis, Radiology, 221, 137, 10.1148/radiol.2211010039

London, 1994, Subintimal angioplasty of femoropopliteal artery occlusions: the long-term results, Eur J Vasc Surg, 8, 148, 10.1016/S0950-821X(05)80450-5

Desgranges, 2004, Subintimal angioplasty: feasible and durable, Eur J Vasc Endovasc Surg, 28, 138, 10.1016/S1078-5884(04)00114-5

Cejna, 2001, PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study, J Vasc Interv Radiol, 12, 23, 10.1016/S1051-0443(07)61397-9

Grimm, 2001, Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions, J Vasc Interv Radiol, 12, 935, 10.1016/S1051-0443(07)61572-3

Vroegindeweij, 1997, Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study, Cardiovasc Intervent Radiol, 20, 420, 10.1007/s002709900186

Schillinger, 2002, Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis, Radiology, 225, 21, 10.1148/radiol.2251011809

Schillinger, 2006, Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery, N Engl J Med, 354, 1879, 10.1056/NEJMoa051303

Wolf, 1993, Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. Principal investigators and their Associates of Veterans Administration Cooperative Study Number 199, J Vasc Interv Radiol, 4, 639, 10.1016/S1051-0443(93)71939-9

Adam, 2005, Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial, Lancet, 366, 1925

Conte, 2001, Impact of increasing comorbidity on infrainguinal reconstruction: a 20 year perspective, Ann Surg, 233, 445, 10.1097/00000658-200103000-00021

Lam, 2004, Risk factors for autogenous infrainguinal bypass occlusion in patients with prosthetic inflow grafts, J Vasc Surg, 39, 336, 10.1016/j.jvs.2003.09.031

Albers, 2003, Meta-analysis of polytetrafluoethylene bypass grafts to infrapopliteal arteries, J Vasc Surg, 37, 1263, 10.1016/S0741-5214(02)75332-9

Jackson, 2000, The consequences of a failed femoropopliteal bypass grafting: comparison of saphenous vein and PTFE grafts, J Vasc Surg, 32, 498, 10.1067/mva.2000.108634

Green, 2000, Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial, J Vasc Surg, 31, 417, 10.1067/mva.2000.103238

AbuRahma, 1999, Prospective controlled study of polytetrafluoroethylene versus saphenous vein in claudicant patients with bilateral above knee femoropopliteal bypasses, Surgery, 126, 594, 10.1016/S0039-6060(99)70110-8

Johnson, 2000, A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization: a prospective randomized Department of Veterans Affairs cooperative study, J Vasc Surg, 32, 268, 10.1067/mva.2000.106944

Klinkert, 2003, Polytetrafluoroethylene femorotibial bypass grafting: 5-year patency and limb salvage, Ann Vasc Surg, 17, 486, 10.1007/s10016-003-0036-8

Hamsho, 1999, Prospective randomised trial of distal arteriovenous fistula as an adjunct to femoro-infrapopliteal PTFE bypass, Eur J Vasc Endovasc Surg, 17, 197, 10.1053/ejvs.1998.0671

Griffith, 2004, Randomized clinical trial of distal anastomotic interposition vein cuff in infrainguinal polytetrafluoethylene bypass grafting, Br J Surg, 91, 560, 10.1002/bjs.4501

Davies, 2005, Is duplex surveillance of value after leg vein bypass grafting? Principal results of the Vein Graft Surveillance Randomised Trial (VGST), Circulation, 112, 1985, 10.1161/CIRCULATIONAHA.104.518738

Baldwin, 2004, Limb salvage following infrainguinal bypass graft failure, J Vasc Surg, 39, 951, 10.1016/j.jvs.2004.01.027

Tangelder, 1999, Systematic review of randomized controlled trials of aspirin and oral anticoagulants in prevention of graft occlusion and ischemic events after infrainguinal bypass surgery, J Vasc Surg, 30, 701, 10.1016/S0741-5214(99)70109-6

Girolami, 2000, Antiplatelet therapy and other interventions after revascularization procedures in patients with peripheral arterial disease: a meta-analysis, Eur J Vasc Endovasc Surg, 19, 370, 10.1053/ejvs.1999.1034

Dorffler-Melly, 2003, Antithrombotic agents for preventing thrombosis after peripheral bypass surgery, Cochrane Database Syst Rev, CD000536

Visser, 2001, Duplex scan surveillance during the first year after infrainguinal autologous vein bypass grafting surgery: costs and clinical outcomes compared with other surveillance programs, J Vasc Surg, 33, 123, 10.1067/mva.2001.109745

Duda, 2002, Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results, Circulation, 106, 1505, 10.1161/01.CIR.0000029746.10018.36

Saxon, 2003, Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery: single center experience from a prospective, randomized trial, J Vasc Interv Radiol, 14, 303, 10.1097/01.RVI.0000058425.01661.d0

Minar, 2000, Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study, Circulation, 102, 2694, 10.1161/01.CIR.102.22.2694

Rutherford, 1979, Combining segmental systolic pressures and plethysmography to diagnose arterial occlusive disease of the legs, Am J Surg, 138, 211, 10.1016/0002-9610(79)90372-6

Koelemay, 2001, Interobserver variation in interpretation of arteriography and management of severe lower leg arterial disease, Eur J Vasc Endovasc Surg, 21, 417, 10.1053/ejvs.2001.1328

de Vries, 2005, Contrast-enhanced peripheral MR angiography using SENSE in multiple stations: feasibility study, J Magn Reson Imaging, 21, 37, 10.1002/jmri.20240

Vogt, 2004, Venous compression at high-spatial-resolution three-dimensional MR angiography of peripheral arteries, Radiology, 233, 913, 10.1148/radiol.2332031367

Dorweiler, 2002, Pedal arterial bypass for limb salvage in patients with diabetes mellitus, Eur J Vasc Endovasc Surg, 24, 309, 10.1053/ejvs.2002.1735

Jakobs, 2004, MDCT-imaging of peripheral arterial disease, Semin Ultrasound CT MR, 25, 145, 10.1016/j.sult.2004.02.003

Ota, 2004, MDCT compared with digital subtraction angiography for assessment of lower extremity arterial occlusive disease: importance of reviewing cross-sectional images, AJR Am J Roentgenol, 182, 201, 10.2214/ajr.182.1.1820201